Picankibart

Innovent Biologics will present research findings at the 34th EADV Congress, showcasing data on IBI112 (picankibart) and preclinical results for IBI3013 and IAR129 via ePosters. Presentations include post-hoc analyses from Phase 2 and 3 trials of picankibart in psoriasis patients, focusing on efficacy in specific areas like the scalp and genitals, as well as comparisons between biologic-experienced and naive patients. Data on IBI3013, targeting IL-15, and IAR129, a bispecific antibody targeting IL-4R/OX40L for atopic dermatitis, will also be presented.